First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Status
- RECRUITING
- Phase
- PHASE3
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
- Status
- RECRUITING
- Phase
- PHASE1
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
- Status
- RECRUITING
- Phase
- PHASE1
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
- Status
- RECRUITING
- Phase
- PHASE2
Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
- Status
- SUSPENDED
- Phase
- PHASE2
Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients
- Status
- RECRUITING
- Phase
- PHASE2
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Status
- RECRUITING
- Phase
- PHASE3
A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)
- Status
- WITHDRAWN
- Phase
- PHASE2
A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)
- Status
- RECRUITING
- Phase
- PHASE2
Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
- Status
- RECRUITING
- Phase
- PHASE2
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Pembrolizumab and Pemetrexed for Progressive Chordoma
- Status
- RECRUITING
- Phase
- PHASE2